Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review

作者：Kulkarni Abhijeet D; Vanjari Yogesh H; Sancheti Karan H; Belgamwar Veena S; Surana Sanjay J; Pardeshi Chandrakantsing V^*

来源：Journal of Drug Targeting, 2015, 23(9): 775-788.

DOI：10.3109/1061186X.2015.1020809

• Blood-brain barrier
• brain-blood ratio
• nanomedicines
• nanotechnology
• nasal drug delivery
• neurodegenerative disorders
• nose to brain
• Parkinson's disease

Nose to brain delivery of neurotherapeutics have been tried by several researchers to explore the virtues of this route viz. circumvention of BBB, avoidance of hepatic metabolism, practicality, safety, ease of administration and non-invasiveness. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson's disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This review presents a concise incursion into the nanomedicines suitable for PD therapy delivered via naso-brain transport. Clinical signs of PD, its pathophysiology, specific genetic determinants, diagnosis and therapy involved have been hashed out. Properties of brain-targeting NPs, transport efficacy and various nanocarriers developed so far also been furnished. In our opinion, nanotechnology-enabled naso-brain drug delivery is an excellent means of delivering neurotherapeutics and is a promising avenue for researchers to develop new formulations for the effective management of PD.

• 出版日期2015-10-21